ASCENDIS PHARMA A/S - ADR (ASND)
US04351P1012 - ADR
ASCENDIS PHARMA A/S - ADR
NASDAQ:ASND (1/14/2025, 8:24:19 PM)
Premarket: 134 +2.43 (+1.85%)131.57
-2.47 (-1.84%)
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Company Info
ASCENDIS PHARMA A/S - ADR
Tuborg Boulevard 12
Hellerup 2900
P: 4570222244
CEO: Jan Moller Mikkelsen
Employees: 879
Website: https://ascendispharma.dk/
ASND News
3 days ago - Ascendis PharmaAscendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today...
9 days ago - Ascendis PharmaAscendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceCOPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the...
a month ago - Ascendis PharmaYORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in AdultsCOPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed...
a month ago - Ascendis PharmaNew InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety...
a month ago - Ascendis PharmaFDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyPDUFA goal date is July 27, 2025...
2 months ago - Ascendis PharmaAscendis Pharma Reports Third Quarter 2024 Financial Results– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA...
ASND Twits
Here you can normally see the latest stock twits on ASND, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
